hCG Supplementation in Frozen-Thawed Embryo Transfer Cycle
Information source: Hadassah Medical Organization
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Fertility Agents, Female
Intervention: s.c. human chorionic gonadotropin (Ovitrelle) (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Hadassah Medical Organization Official(s) and/or principal investigator(s): Assaf Ben-Meir, MD, Principal Investigator, Affiliation: Hadassah Medical Organization
Summary
The implantation rate after frozen-thawed embryo transfer cycles depends mostly on the
receptivity of the endometrium and the embryo quality. The effects of human chorionic
gonadotropins (hCG) on the endometrium have been investigated for several years. hCG was
shown to up-regulate gene expression during the differentiation of human endometrial stromal
cells into decidua. The aim of our study was to assess the benefit of hCG supplementation
throughout the secretory phase of artificial frozen-thawed embryo transfer cycles.
Clinical Details
Official title: The Benefit of Human Chorionic Gonadotropin (hCG) Supplementation Throughout the Secretory Phase of Frozen-Thawed Embryo Transfer Cycles
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: implantation ratepregnancy rate
Eligibility
Minimum age: 18 Years.
Maximum age: 45 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- all women on frozen-thawed embryo-transfer cycle
Exclusion Criteria:
- any allergy to injection of human chorionic gonadotropin before
Locations and Contacts
Hadassah Medical center, Jerusalem, Israel
Additional Information
Starting date: November 2006
Last updated: December 31, 2008
|